Karyopharm Therapeutics Inc

NASDAQ:KPTI   3:59:58 PM EDT
10.57
-0.01 (-0.10%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)793.69M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$26.33 Million
Adjusted EPS-$0.73
See more estimates
10-Day MA$10.20
50-Day MA$9.46
200-Day MA$13.35
See more pivots

Karyopharm Therapeutics Inc Stock, NASDAQ:KPTI

85 Wells Avenue, 2nd floor, Newton, Massachusetts 02459
United States of America
Phone: +1.617.658.0600
Number of Employees: 432

Description

Karyopharm Therapeutics, Inc. is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Its SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharmâ??s lead compound, XPOVIOTM (selinexor), received accelerated approval from the FDA in combination with dexamethasone as a treatment for patients with pretreated multiple myeloma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.